Osvyrti is suppled as a 60mg/mL single-dose prefilled syringe for SC administration and Jubereq is supplied as 120mg/1.7mL single-dose vial for SC administration.
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology ...
FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.
US FDA approves Accord BioPharma’s denosumab biosimilars Osvyrti and Jubereq: Raleigh, North Carolina Friday, November 21, 2025, 18:00 Hrs [IST] Accord BioPharma, Inc., the spec ...
The FDA has approved two new drugs that are biosimilars to denosumab, adding to the ever-expanding field of less expensive options of the popular anti-osteoporosis and cancer-related bone loss drug; ...
Hosted on MSN
Biocon gains on U.S. entry for denosumab biosimilars
Mumbai, Oct. 1 -- The pact clears the way for the U.S. launch of denosumab biosimilars Bosaya and Aukelso from 1 October 2025. The agreement settles ongoing patent litigation in the U.S. District ...
Amgen Files BPCIA Complaints Against Dr. Reddy’s/Alvotech and Amneal Regarding Denosumab Biosimilars
On November 6, 2025, Amgen, Inc. (“Amgen”) launched a new round of BPCIA denosumab litigations when it filed two cases in the U.S. District Court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback